Evaluation and Management of Cognitive Decline in Elderly Patients

Initial Assessment

The American Geriatrics Society recommends beginning with a structured cognitive assessment using the Montreal Cognitive Assessment (MoCA), which is more sensitive than the MMSE for detecting mild cognitive impairment, and obtaining collateral history from a reliable informant to corroborate cognitive decline and assess functional impairment in instrumental activities of daily living 1, 2
Administer the MoCA as the first-line screening tool with a sensitivity of 90% compared to 75% for MMSE in detecting mild cognitive impairment 1, 2
Alternative validated brief tools include the Mini-Cog, Memory Impairment Screen plus Clock Drawing Test, or the GP Assessment of Cognition if time is limited 3
Document baseline cognitive performance across all domains: attention, concentration, short- and long-term memory, language, executive function, visuospatial abilities, praxis, and behavior 2, 4

Obtaining information from a family member or close contact is mandatory, as informant reports provide added value with 80% sensitivity and 90% specificity for disease detection 5, 2
Ask specifically about changes in instrumental activities of daily living: managing finances, medications, transportation, household management, cooking, shopping, and ability to follow instructions 3, 4
Use structured scales: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Lawton Instrumental Activities of Daily Living Scale, or Pfeffer Functional Activities Questionnaire 6, 4
Screen for depression using the Patient Health Questionnaire-9 (PHQ-9), as depression frequently presents with cognitive complaints and is a treatable cause 1, 4
Screen for anxiety using GAD-7 6
Assess for neuropsychiatric symptoms using the Neuropsychiatric Inventory-Questionnaire (NPI-Q) or Mild Behavioural Impairment Checklist (MBI-C) 6, 4

Order thyroid function tests (TSH, free T4) to exclude hypothyroidism, which has a 10% prevalence in elderly patients and mimics dementia 7, 1, 2
Order vitamin B12, folate, methylmalonic acid, and homocysteine levels with 85% sensitivity and 90% specificity for identifying deficiency-related cognitive impairment 1, 2
Immediately review and discontinue all medications that impair cognition, as this is often the most reversible cause of memory deficits in elderly patients 2
Identify and taper benzodiazepines (lorazepam, clonazepam, diazepam) which cause sedation, cognitive impairment, and fall risk with a relative risk of 1.5 2
Discontinue sedative-hypnotics (zolpidem, zaleplon, zopiclone) which directly contribute to cognitive impairment with a hazard ratio of 2.1 2

Obtain brain MRI (preferred over CT) if any of the following are present: cognitive symptoms with onset within the last 2 years, unexpected or rapid decline in cognition or function, recent significant head trauma, unexplained neurological manifestations or focal neurological signs, significant vascular risk factors, or age less than 60 years with cognitive decline 1
Distinguish between subjective cognitive decline, mild cognitive impairment (MCI), and dementia based on patient reports, cognitive testing, and impairment in instrumental activities of daily living 6, 3, 2, 4

Do not delay B12 replacement while waiting for test results if clinical suspicion is high, as this can lead to irreversible neurologic damage 2
Treat hypothyroidism, metabolic disturbances, depression, or other identified conditions 7, 1
Discontinue offending medications 2
Do not prescribe cholinesterase inhibitors for MCI—evidence does not support their use in this population 1
Recommend group or individual physical exercise, which represents the strongest evidence-based intervention with Level 1B recommendation 1
Provide group cognitive stimulation therapy 1
Counsel on WHO recommendations for dementia prevention 6
Refer to neurology or geriatrics for formal neuropsychological evaluation 4
Consider cholinesterase inhibitors for mild to moderate Alzheimer's disease 4
Implement cognitive stimulation therapy and educate caregivers 4
Schedule comprehensive reassessment every 6-12 months for stable patients, or every 3-4 months if behavioral symptoms or rapid decline occur 1, 4
Use multi-dimensional approach monitoring cognition, functional autonomy, behavioral symptoms, and caregiver burden 6, 4

Do not attribute all symptoms to "normal aging" without proper workup, as 20% of elderly patients have reversible causes 2
Do not start cholinesterase inhibitors without excluding reversible causes like B12 deficiency, hypothyroidism, and medication effects, which can worsen cognitive impairment with a hazard ratio of 1.8 2
Do not overlook depression and anxiety, which are highly prevalent, treatable causes of cognitive complaints in this age group 1
Do not ignore vascular risk factors—aggressive management of hypertension (goal systolic BP <120 mmHg) reduces dementia risk with absolute risk reduction of 0.4-0.7% per year 1